Trials demonstrating efficacy or non-inferiority of SGLT2 in heart failure include the empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME) trial [39]; canagliflozin cardiovascular assessment study (CANVAS) [34,40], and multicenter trial to evaluate the effect of dapagliflozin on incidence of cardiovascular events (DECLARE-TIMI 58) [40]. The gene discussed is SLC5A2; the disease is heart failure.